Adherence Toolkit for Managing Nonadherence to HIV Medications in Indonesia

A Practical Adherence Toolkit for Managing Nonadherence to HIV Medications in Indonesia: Protocol for a Usability Study and Cluster Randomised Controlled Trial

The goal of this usability study and a cluster randomised controlled trial is to investigate the effectiveness of an adherence toolkit as a decision support tool to improve adherence to antiretroviral therapy. The main questions it aims to answer are: 1) is the adherence toolkit useable and acceptable among HIV care providers in Indonesian clinical practice? and 2) is the adherence toolkit superior than the usual care in improving adherence to antiretroviral therapy among people living with HIV in Indonesia? HIV clinics in Surabaya, Indonesia, will be recruited to participate in the study. HIV care providers will be included in the usability study, whereas people living with HIV will be enrolled in the cluster randomised controlled trial. People living with HIV will be randomly assigned in a 1:1 ratio to the control group receiving usual HIV care and the intervention group receiving an intervention using the adherence toolkit in addition to usual HIV care.

Study Overview

• Status: Not yet recruiting
• Conditions: HIV Infections; Adult
• Intervention / Treatment: Behavioral: Adherence toolkit

Detailed Description

Consistent adherence to antiretroviral therapy (ART) is important to maintain viral suppression and good quality of life among people living with HIV. However, maintaining a high level of ART adherence is challenging because adherence is a complex behaviour and many factors contribute to nonadherence. Therefore, a decision support tool is proposed to help HIV care providers in addressing the barriers and providing the adherence-promoting interventions tailored to the individual needs. The present study comprises a usability assessment followed by a cluster randomised controlled trial to investigate the effectiveness of the adherence toolkit as a decision support tool on improving adherence to ART. Twelve HIV clinics in Surabaya, Indonesia, will be randomised 1:1 to the control (usual care) and intervention (adherence toolkit and usual care) group. The intervention period will last for 12 months, with outcome measures will be collected at initiation, 3-, 6-, and 12-month post-initiation. The primary outcome is adherence to ART measured using a self-reported adherence questionnaire and pharmacy refill records. The secondary outcomes include clinical outcomes (viral load, CD4), HIV treatment knowledge, medication beliefs, and health-related quality of life. The findings will enable HIV care providers, people living with HIV, and policy makers to make informed decision about the value of the adherence toolkit for being used in daily clinical practice.

• Study Type: Interventional
• Enrollment (Estimated): 400
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Tri Pudy Asmarawati, MD; Email: tpasmarawati@fk.unair.ac.id
• Study Contact Backup: Name: Zamrotul Izzah, MSc; Phone Number: 6285655191257; Email: zamrotulizzah@ff.unair.ac.id

Study Locations

• Indonesia
  • Surabaya, Indonesia
    • HIV clinics
    • Contact: Maya Kristinawati

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Doctors, nurses, and pharmacists who have been trained to provide HIV care and treatment by the Indonesian Ministry of Health
• People living with HIV who have been receiving any ART regimens for at least six months, aged 18 years and older, with any coinfection or comorbidity, suspected to be nonadherent to HIV medications (e.g., having sustained treatment interruptions, inconsistent prescription refill, increased viral load >1,000 copies/ml, decreased CD4 count <200 cells/mm3, or developed opportunistic infections), and provided informed consent

Exclusion Criteria:

• People who have severe mental or physical constraints, drop-out or withdraw after the commencement of the trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control; Individuals in the HIV clinics randomised to the control or intervention group will attend a consultation session as a usual HIV care based on the Indonesian guideline for HIV care and treatment (Ministry of Health Regulation No. 23/2022). Although it may slightly vary by clinic, for every visit they will collect their medications and receive general information from the HIV care provider on the prescribed ART regimens, including the dose, time of administration, potential side effects and how to deal with them, and the importance of adherence. They will be followed-up at the same time points as those in the intervention group.
Experimental: Intervention; Individuals attending the HIV clinics that are randomised to the intervention group will receive an intervention over 12 months in addition to usual care. The intervention using an adherence toolkit will be delivered during regular clinic visits when they collect their medications.	Behavioral: Adherence toolkit; The adherence toolkit consists of a flowchart of adherence intervention, a self-reported adherence questionnaire, and an intervention wheel as a decision support tool for a healthcare provider. The toolkit can guide HIV care providers to identify problems causing nonadherence and to tailor the effective interventions based on the individual problems. It is available in a Bahasa Indonesia version, accompanied by a user guide on the practical application of the intervention, and can be used digitally or printed on paper. The intervention wheel is an integrated HIV medication adherence influencing factors and effective adherence-promoting interventions derived from systematic reviews and meta analyses, including previous studies conducted in Indonesia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adherence to antiretroviral therapy (ART)	The primary outcome of the trial is the difference in the changes of adherence rates between the intervention and the control group. The outcome will be repeatedly measured as proportion of people who adhere to ART in the intervention and control groups at study initiation and during the follow-up periods using a previously validated self-reported adherence questionnaire and pharmacy refill data.	0, 3, 6, and 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Viral load	The viral load test will measure the number of HIV copies in a milliliter of plasma (in copies/ml).	0 and 12 months
CD4 cell count	The CD4 cell count will measure the number of CD4 cells in plasma (in cells/mm^3).	0 and 12 months
HIV treatment knowledge	HIV treatment knowledge will be assessed using a validated Bahasa Indonesia version of 8-item brief estimate of health knowledge and action-HIV questionnaire. The questionnaire comprises eight statements, three items assessing HIV knowledge and five items evaluating treatment action. Each response is assigned a score of 0, indicating an incorrect, unsure, or disagree answer, or score 1, indicating a correct or agree answer. The total scores range from 0 to 8, and higher scores correspond with adequate HIV treatment knowledge.	0, 3, 6, and 12 months
Medication beliefs	Medication beliefs will be examined by a validated Bahasa Indonesia version of the 18-item beliefs about medicines questionnaire. The questionnaire consists of two sections with 18 statements. The general section contains two four-item scales asking about medication beliefs in general, relating to medication harm (General-Harm) and overuse (General-Overuse). The specific section comprises two five-item scales asking about the necessity of prescribed medication (Specific-Necessity) and concerns about its negative effects (Specific-Concerns). The response for each statement is given on a 5-point Likert scale, where 1 means "Strongly disagree" and 5 means "Strongly agree". The total scores for the harm and overuse scales range from 5 to 20, while for necessity and concerns range from 5 to 25. Higher scores denote stronger medication beliefs.	0, 3, 6, and 12 months
Health-related quality of life	Health-related quality of life will be determined by a validated Bahasa Indonesia version of the 31-item World Health Organization (WHO) quality of life-HIV brief questionnaire. The questionnaire contains 31 questions that examine general quality of life (questions 1 and 2) and six domains of health-related quality of life including physical health (questions 3, 4, 14, and 21), psychological health (questions 6, 11, 15, 24, and 31), level of independence (questions 5, 20, 22, and 23), social relationships (questions 17, 25, 26, and 27), environmental health (questions 12, 13, 16, 18, 19, 28, 29, and 30), and spirituality/personal beliefs (questions 7, 8, 9, and 10). Individual items are rated on a 5-point Likert scale where 1 indicates a negative perception and 5 indicates a positive perception. Scoring and coding of each domain follows the instructions provided by WHO, so that each domain scores range between 4 and 20 with higher scores reflect better quality of life.	0, 3, 6, and 12 months
Usability	A Bahasa Indonesia version of validated system usability scale questionnaire will be used to measure the usability of the adherence toolkit. The questionnaire consists of ten statements with answers given on a 5-point Likert scale, ranging from "Strongly disagree" (1) to "Strongly agree" (5). The total scores range from 0 to 100, with a higher score indicating higher perceived usability and a score of 68 is considered the average.	1 month
Acceptability	A one-on-one interview will be performed to explore the perception of HIV care providers on acceptance, experience, and room for improvement of the adherence toolkit.	12 months

Collaborators and Investigators

• Sponsor: University of Groningen
• Collaborators: Universitas Airlangga
• Investigators: Principal Investigator: Zamrotul Izzah, MSc, Universitas Airlangga

Study record dates

Study Major Dates

• Study Start (Estimated): January 2, 2024
• Primary Completion (Estimated): June 30, 2025
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: July 21, 2023
• First Submitted That Met QC Criteria: August 10, 2023
• First Posted (Actual): August 16, 2023

Study Record Updates

• Last Update Posted (Actual): August 16, 2023
• Last Update Submitted That Met QC Criteria: August 10, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Adherence; HIV; Quality of life; Antiretroviral therapy; Medication beliefs; Treatment knowledge
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; Urogenital Diseases; Genital Diseases; HIV Infections
• Other Study ID Numbers: V1-072023

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: De-identified data will be available only to authorised persons for analysis and reporting purposes.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No